A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 in Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2018
At a glance
- Drugs ETC 1922159 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 05 Jan 2018 Planned number of patients changed from 65 to 75.
- 22 Jun 2017 Planned number of patients changed from 58 to 65.
- 22 Jun 2017 Planned End Date changed from 1 Apr 2018 to 1 Aug 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History